Serum macrophage-derived chemokine/CCL22 levels are associated with glioma risk, CD4 T cell lymphopenia and survival time.

摘要: Defects in antigen presenting cell function have been implicated glioma immunosuppression. We measured peripheral CCL22, a dendritic cell/macrophage derived T trafficking chemokine, sera from 1,208 cases and 976 controls to assess whether it might provide biomarker of risk, survival immune dysfunction. Cluster models were used examine the relationship between CCL22 risk. Patient was assessed using Cox regression models. also examined levels CD4 counts, as well allergy history IgE levels. significantly lower among compared with (Mean ± SEM: 1.23 0.03 ng/mL vs. 1.60 controls, p < 0.0001) this difference remained significant even after controlling for other covariates cluster (highest quartile versus lowest Odds Ratio = 0.21, 0.0001). counts positively correlated (Spearman r(2) 0.51, 0.01) controls. Higher associated longer all combined GBM (hazard ratio(allcases) = 0.81; 95% CI: 0.72-0.91, 0.0003). not level or self-reported allergies. Circulating are related both risk duration independent age, histology, grade IDH mutation status. should be considered marker status potential prognostic value.